Market Newsdesk

• Analysis of blood samples from patients treated with Aramchol in ARMOR (Ph3 MASH Study) provides new and important insights into the biochemical and physiological effects of the drug.
• The pharmacodynamic signature associated with Aramchol treatment revealed a decrease in markers of chronic systemic inflammation, oxidative and cardiac stress, and atherosclerotic plaque pathogenesis.
• Data also show a significant decrease in ANP (Atrial Natriuretic Peptide), a clinically validated marker for heart failure.
  

TEL AVIV, Israel
, April 15, 2025 /PRNewswire/ — Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing novel treatments for liver, cardiometabolic, and gastrointestinal oncology indications, today announces the unveiling of novel pharmacodynamic (PD) blood markers for its lead compound, Aramchol, the industry’s most clinically advanced SCD1 inhibitor. These newly identified biomarkers shed fresh light on Aramchol’s potential far beyond its role in NASH (MASH) therapy—offering a deeper understanding of the drug candidate’s biochemical impact and presenting an exciting opportunity to enhance clinical decision-making and expand into additional disease areas.

In collaboration with Proteas Health, a leader in innovative protein biomarker and targeted assay development, Galmed has pinpointed plasma markers that track Aramchol’s therapeutic impact through cutting-edge proteomics and AI technologies. Specifically, a panel of 70 proteins expressed at Week 12 of Aramchol treatment (compared with baseline) was captured in the Company’s Phase 3 ARMOR MASH study. This panel forms an actionable, single blood-based pharmacodynamic signature to monitor and potentially predict patient response, encompassing both systemic and local (liver) effects.

Galmed’s analysis revealed that this signature aligns with reduced chronic systemic inflammation, oxidative stress, and atherosclerotic plaque pathogenesis—key drivers in cardiometabolic diseases. Significantly, the data also demonstrate a marked reduction in ANP (Atrial Natriuretic Peptide), widely recognized as an established clinical biomarker for heart failure and left ventricular dysfunction. Moreover, the findings indicate a stimulated expression of KDM4C, a protein known to play a role in repressing liver fibrosis. Altogether, these insights underscore Aramchol’s broad therapeutic relevance and create valuable opportunities for Galmed to expand its clinical pipeline and address additional cardiometabolic and potentially oncological indications.

Allen Baharaff, CEO of Galmed Pharmaceuticals commented: “The newly discovered markers showed significant expression in untreated patients at baseline and were reversed following treatment with Aramchol. These PD markers could serve as a liquid biopsy as an early indicator of Aramchol’s efficacy in clinical settings. Additionally, the observed significant effects on cardiometabolic biomarkers open future research avenues for Aramchol in CVD and related conditions”.

The collaboration with Proteas Health aims to translate these discoveries into a streamlined, cost-efficient, high-throughput assay that directly measures Aramchol’s unique PD signature. Such an assay, once validated, could bolster Galmed’s forthcoming clinical trials by further de-risking development and allowing clinicians to evaluate drug response in real time.

“Through this collaboration, Proteas Health and Galmed aim to develop a cost-effective, high-throughput assay targeting Aramchol’s unique pharmacodynamic signature. This assay could play a pivotal role in Galmed’s future clinical trials, accelerating the efforts to bring Aramchol to market” said Dr. Antigoni Manousopoulou, MD, PhD, Co-Founder and Chief Scientific Officer at Proteas Health. “By focusing on targeted pharmacodynamic biomarkers, Proteas Health is not just enhancing drug development Proteas Health ensuring therapies are tailored to achieve maximum benefit with minimal risk.”

These promising data underscore Galmed’s growing momentum: by combining innovative biomarker strategies with Aramchol’s safety and efficacy profile, the Company believes it is well-positioned to broaden its market reach and deliver significant value to patients and stakeholders alike. Given the global burden of cardiometabolic and fibro-inflammatory conditions, the ability to demonstrate and monitor Aramchol’s impact through a single blood test has the potential to transform future clinical development and create new horizons for commercialization.

About Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. is a biopharmaceutical company focused on the development of Aramchol. The Company has concentrated almost exclusively on advancing Aramchol for the treatment of liver disease and is currently pursuing development of Aramchol in oncological indications beyond NASH and fibrosis. As part of its growth strategy, Galmed is actively exploring opportunities to expand and diversify its product pipeline—particularly in cardiometabolic indications and other innovative product candidates aligned with the Company’s core drug-development expertise.

About Proteas Health

Proteas Health has pioneered a cutting-edge liquid biopsy platform technology to identify and analyze proteins as pharmacodynamic signatures of drug mechanisms in specific diseases. By enabling pharmaceutical companies to verify safety and efficacy profiles—including proof of mechanism—Proteas Health’s solutions are designed to reduce clinical trial risk and accelerate pathways to commercialization, making it an integral partner in modern drug development.

Forward-Looking Statements:

Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our product development efforts, business, financial condition, results of operations, strategies or prospects, including the potential of the PD markers for Aramchol, as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, believes or anticipate will or may occur in the future. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the development and approval of the use of Aramchol or any other product candidate for indications outside of non-alcoholic steatohepatitis, or NASH, also known as metabolic dysfunction-associated steatohepatitis, or MASH, and fibrosis or in combination therapy; the timing and cost of any pre-clinical or clinical trials of Aramchol or any other product candidate we develop; completion and receiving favorable results of any pre-clinical or clinical trial; regulatory action with respect to Aramchol or any other product candidate by the U.S. Food and Drug Administration, or the FDA, or the European Medicines Authority, or EMA, including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; the commercial launch and future sales of Aramchol and any future product candidates; our ability to comply with all applicable post-market regulatory requirements for Aramchol, or any other product candidate in the countries in which we seek to market the product; our ability to achieve favorable pricing for Aramchol, or any other product candidate; third-party payor reimbursement for Aramchol, or any other product candidate; our estimates regarding anticipated capital requirements and our needs for additional financing; market adoption of Aramchol or any other product candidate by physicians and patients; the timing, cost or other aspects of the commercial launch of Aramchol or any other product candidate; our ability to obtain and maintain adequate protection of our intellectual property; the possibility that we may face third-party claims of intellectual property infringement; our ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; our ability to establish adequate sales, marketing and distribution channels; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; our expectations regarding licensing, acquisitions and strategic operations; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; our ability to maintain the listing of our ordinary shares on The Nasdaq Capital Market; and security, political and economic instability in the Middle East that could harm our business, including due to the current security situation in Israel. We believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on April 2, 2025 in greater detail under the heading “Risk Factors.” Given these uncertainties, you should not rely upon forward-looking statements as predictions of future events. All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date hereof and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.

Logo: https://mma.prnewswire.com/media/1713483/5268729/Galmed_Pharmaceuticals_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/galmed-unveils-novel-pharmacodynamic-blood-markers-for-aramchol-the-most-clinically-advanced-scd1-inhibitor-302428834.html

SOURCE Galmed Pharmaceuticals Ltd.

NEW YORK and TOKYO and TAIPEI, April 15, 2025 /PRNewswire/ — TNL Mediagene (Nasdaq: TNMG), Asia’s next-generation digital media and data group, today announced a strategic partnership with one of Taiwan’s leading e-commerce brands, PChome Online (Stock Code: 8044-TW). This collaboration marks a significant step in shifting the retail media ecosystem by integrating the DNA of Content Marketing and Affiliate Marketing to launch an innovative Content Commerce operation methodology. Using high-quality content to directly drive conversion, this approach will actively promote products across various industry sectors on PChome.

Following TNL Mediagene’s successful listing on Nasdaq, this collaboration underscores the company’s commitment to expanding its business promotion landscape through innovation. With PChome 24h Shopping and PChome Online recognized as pioneers of Taiwan’s e-commerce evolution, the partnership will leverage the powerful media assets under the group’s umbrella – including The News Lens, INSIDE, Sport Vision, Cool3C etc., to boost content commerce initiatives. The collaboration will utilize diverse content formats, narrative techniques, and interactive elements such as call-to-action buttons, hyperlinks, and exclusive discount codes to attract consumer interest and drive purchases.

TNL Mediagene’s subsidiary, Mediagene Inc., which operates as one of Japan’s leading native digital media companies, achieved excellent results in content commerce across multiple platforms and suppliers in Japan. The group is now actively extending these successful strategies into the Taiwan market.

Integrating Technology and Expertise to build a highly efficient collaboration model

In this collaboration, TNL Mediagene will execute an end-to-end strategy encompassing planning, execution, optimization, and measurement. Utilizing a scientifically driven tech system, the group aims to ensure the quality, traffic, and conversion effectiveness of marketing content.

• Planning: By analyzing the characteristics of different product categories and the timing of campaign events, the team will develop tailored media and content strategies (for example, designing dedicated themes to captivate young consumers for technology products).
• Execution & Optimization: Efforts in these stages will focus on enhancing content reach and driving sales performance. Adjustments in content formats will be made to attract increased attention, while system-driven data will continuously optimize the process.
• Measurement: The success of these initiatives will be gauged by conversion outcomes. A technology platform will track and analyze marketing results comprehensively to ensure a precise response to market demands.

The campaign intends to promote home appliances and PC-related products through flagship news and technology media such as TNL, INSIDE, and Cool3C. Meanwhile, sports, leisure, and lifestyle products will be featured via channels including Sport Vision, the international Chinese edition of Roomie, and every little d., leveraging each media brand’s content strengths and data analytics to boost conversion performance.

Committed to the principle of “Brandformance”—a marketing strategy that enhances brand equity while delivering measurable results—TNL Mediagene fuses media credibility, strategic storytelling, and robust data insights. This dual-focus approach drives both awareness and action, ensuring marketing not only reaches audiences but also converts them. In collaboration with PChome, this philosophy will guide the creation of diversified, high-impact media strategies.

CEO and Co-Founder Joey Chung commented, “Content commerce is not only an innovative model that blends media with business but also an essential element of the retail media ecosystem. We are honored to partner with a key player like PChome to seamlessly integrate high-quality content with e-commerce, delivering a more engaging shopping experience for consumers.”

About PChome Online

Founded in 1998, PChome Online is Taiwan’s leading e-commerce group, committed to delivering a diverse and convenient shopping experience for consumers. Its core operations include PChome 24h Shopping, the PChome Online website, and a suite of digital services and applications covering sectors such as e-commerce, fintech, and empowerment services. PChome is one of Taiwan’s pioneering e-commerce entities and became the first internet company to be listed on the Taiwan Stock Exchange in 2005. Through innovative technologies and service models, PChome continues to address the increasingly diverse needs of consumers and plays a pivotal role in advancing Taiwan’s digital lifestyle.

About TNL Mediagene

Registered in the Cayman Islands, TNL Mediagene was formed in May 2023 through the merger of Taiwan’s The News Lens Co. and Japan’s Mediagene Inc., two of the region’s leading independent digital media groups. The company’s operations span original and licensed media brands in Chinese, Japanese, and English, covering topics such as news, business, technology, science, food, sports, and lifestyle. It also offers AI-driven advertising services, marketing technology platforms, e-commerce, and innovative solutions tailored to the needs of advertising agencies. Known for its political neutrality, appeal to younger audiences, and high-quality content, TNL Mediagene has approximately 550 employees across Asia, with offices in Japan, Taiwan, and Hong Kong.

https://www.tnlmediagene.com/ 

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on beliefs and assumptions and on information currently available to TNL Mediagene. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “target,” “seek” or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including strategies or plans, are also forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Forward-looking statements in this communication or elsewhere speak only as of the date made. New uncertainties and risks arise from time to time, and it is impossible for TNL Mediagene to predict these events or how they may affect TNL Mediagene. In addition, risks and uncertainties are described in TNL Mediagene’s filings with the Securities and Exchange Commission. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. TNL Mediagene cannot assure you that the forward-looking statements in this communication will prove to be accurate. There may be additional risks that TNL Mediagene presently does not know or that TNL Mediagene currently does not believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by TNL Mediagene, its directors, officers or employees or any other person. Except as required by applicable law, TNL Mediagene does not have any duty to, and does not intend to, update or revise the forward-looking statements in this communication or elsewhere after the date of this communication. You should, therefore, not rely on these forward-looking statements as representing the views of TNL Mediagene as of any date subsequent to the date of this communication.

View original content to download multimedia:https://www.prnewswire.com/news-releases/tnl-mediagene-and-pchome-forge-strategic-alliance-to-accelerate-content-commerce-and-reshape-taiwans-retail-media-landscape-302428862.html

SOURCE TNL Mediagene

Starting April 17, guests can indulge in a brand new Pizookie® where melted cheddar and tender broccoli are blended into the cookie base and then piled high on top with two scoops of mashed potatoes.

HUNTINGTON BEACH, Calif.
, April 15, 2025 /PRNewswire/ — Just when you thought BJ’s Restaurant & Brewhouse (NASDAQ: BJRI) had reached peak Pizookie® absurdity, we’re back to prove you wrong. After the surge of excitement for the Fryckle Pizookie®, BJ’s is thrilled to introduce another Pizookie® that’s not just a dessert—it’s a flavor revolution.

Prepare yourselves for the Broccoli Cheddar Pizookie®, a culinary masterpiece that defies all dessert conventions. Forget the chocolate chunks—this Pizookie® boasts a cheddar and broccoli base, further enhanced by a decadent topping of melted cheddar and steamed broccoli with two scoops of mashed potatoes. It’s the comfort food combination you never knew you wanted or even needed.

“We’re always pushing the boundaries of flavor, and this time, we’ve struck gold with an unexpected yet utterly delightful combination,” said Heidi Rogers, Senior Vice President of Marketing at BJ’s Restaurants, Inc. “We asked ourselves, ‘What’s the most unexpected, yet undeniably comforting flavor profile we could possibly create?’ And the answer, naturally, was broccoli and cheddar.”

To celebrate this daring new creation, BJ’s is offering the Broccoli Cheddar Pizookie® for a limited time only. It’s a flavor adventure, a conversation starter and a testament to BJ’s unwavering commitment to Pizookie® innovation.

“This isn’t just a dessert; it’s an experience,” Rogers continued. “It’s a celebration of unexpected pairings and the sheer joy of discovering new flavor dimensions. And bonus? We’ve made it incredibly easy and delicious to enjoy vegetables.”

However, for those who prefer the familiar sweetness of our classic Pizookie®, fear not! It’s still here. But, for those ready to embark on a flavor journey, the Broccoli Cheddar Pizookie® awaits.

For more information on the Broccoli Cheddar Pizookie® or to see the full Pizookie® menu, visit www.bjsrestaurants.com or follow @bjsrestaurants on Instagram, Facebook and X.

About BJ’s Restaurants, Inc.
BJ’s Restaurants, Inc. is a national brand with brewhouse roots where Craft Matters®. BJ’s broad menu has something for everyone: slow-roasted entrees, like prime rib, BJ’s EnLIGHTened Entrees® including Cherry Chipotle Glazed Salmon, signature deep-dish pizza and the often imitated, but never replicated world-famous Pizookie® dessert. The winner of the2025 Vibe Vista Award for Best Beer Program, the winner of the 2024 Vibe Vista Award for Best Overall Beverage Program and the most decorated restaurant-brewery in the country, BJ’s has been a pioneer in the craft brewing world since 1996 and takes pride in serving BJ’s award-winning proprietary handcrafted beers, brewed at its brewing operations in four states and by independent third-party craft brewers. The BJ’s experience offers high-quality ingredients, bold flavors, moderate prices, sincere service, and a cool, contemporary atmosphere. Founded in 1978, BJ’s owns and operates over 200 casual dining restaurants in 31 states. All restaurants offer dine-in, take-out, delivery and large party catering. 

Contact
ICR Blue Engine
[email protected] 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bjs-restaurant–brewhouse-goes-green-and-gets-cheesy-with-the-broccoli-cheddar-pizookie-302428277.html

SOURCE BJ’s Restaurants, Inc.

BEIJING
, April 15, 2025 /PRNewswire/ — Autohome Inc. (NYSE: ATHM; HKEX: 2518) (“Autohome” or the “Company”), the leading online destination for automobile consumers in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the United States Securities and Exchange Commission (the “SEC”) on April 15, 2025. The annual report on Form 20-F, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC’s website at https://www.sec.gov as well as through the Company’s investor relations website at https://ir.autohome.com.cn.

The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to Investor Relations Department, Autohome Inc., 18th Floor Tower B, CEC Plaza, 3 Dan Ling Street, Haidian District, Beijing, People’s Republic of China.

The Company has also published the same annual report today for Hong Kong purposes pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “HKEX”), which can be accessed on the Company’s investor relations website at https://ir.autohome.com.cn as well as the HKEX’s website at http://www.hkexnews.hk.

About Autohome Inc.

Autohome Inc. (NYSE: ATHM; HKEX: 2518) is the leading online destination for automobile consumers in China. Its mission is to engage, educate and inform consumers about everything auto. Autohome provides occupationally generated content, professionally generated content, user-generated content, and AI-generated content, a comprehensive automobile library, and extensive automobile listing information to automobile consumers, covering the entire car purchase and ownership cycle. The ability to reach a large and engaged user base of automobile consumers has made Autohome a preferred platform for automakers and dealers to conduct their advertising campaigns. Further, the Company’s dealer subscription and advertising services allow dealers to market their inventory and services through Autohome’s platform, extending the reach of their physical showrooms to potentially millions of internet users in China and generating sales leads for them. The Company offers sales leads, data analysis, and marketing services to assist automakers and dealers with improving their efficiency and facilitating transactions. Further, through its websites and mobile applications, it also provides other value-added services, including auto financing, auto insurance, used car transactions, and aftermarket services. For further information, please visit www.autohome.com.cn.

For investor and media inquiries, please contact:

Autohome Inc.

Sterling Song

Investor Relations Director
Tel: +86-10-5985-7483
E-mail: [email protected]

View original content:https://www.prnewswire.com/news-releases/autohome-inc-files-its-annual-report-on-form-20-f-302428843.html

SOURCE Autohome Inc.

BALTIMORE
, April 15, 2025 /PRNewswire/ — Under Armour, Inc. (NYSE: UA, UAA) announced today that, effective April 15, Dawn N. Fitzpatrick, Eugene D. Smith, and Robert J. Sweeney will join the company’s Board of Directors.

“Dawn and Rob’s extensive financial and operational expertise, combined with Gene’s deep knowledge of intercollegiate sports management, makes them exceptional additions to our board,” said Mohamed A. El-Erian, Chair of the Board at Under Armour. “As we pursue our strategy to create greater value for Under Armour’s athletes, customers, shareholders, and teammates, their unique talents, insights, and passion for the brand will be invaluable for navigating our next chapter.”

Effective April 15, Under Armour’s Board will include Douglas E. Coltharp, Jerri L. DeVard, Mohamed A. El-Erian, Carolyn N. Everson, Dawn N. Fitzpatrick, David W. Gibbs, Karen W. Katz, Eric T. Olson, Kevin A. Plank, Eugene D. Smith, Robert J. Sweeney, and Patrick W. Whitesell.

About Dawn N. Fitzpatrick

Since 2017, Ms. Fitzpatrick has been the Chief Executive Officer and Chief Investment Officer of Soros Fund Management, LLC, a privately held investment management firm. Before joining Soros in 2017, she spent 25 years at UBS and its predecessor organizations, where she most recently served as Head of Investments for UBS Asset Management and was a member of the UBS Asset Management Executive Committee. Earlier, she held several positions at the UBS O’Connor hedge fund business, including Chief Executive Officer and Chief Investment Officer. Ms. Fitzpatrick serves as a non-executive director of Barclays plc and serves on its Remuneration, Risk, and Sustainability Committees. Additionally, she serves on the Federal Reserve Bank of Dallas Financial Sector Advisory Council, where she is Chair, the Advisory Council of The Bretton Woods Committee, and the Bloomberg New Economy Advisory Board. She previously completed a six-year term on the Investor Advisory Committee on Financial Markets at the Federal Reserve Bank of New York. Ms. Fitzpatrick earned her bachelor’s degree from the Wharton School of Business at the University of Pennsylvania, where she ran track and cross country.

About Eugene D. Smith

Mr. Smith served as Senior Vice President and Athletic Director at Ohio State University from 2005 to 2024. Throughout his tenure, he co-chaired the NCAA’s Federal-State Legislative Working Group, which advised the NCAA on name, image, and likeness issues, chaired the 2011 NCAA Men’s Basketball Committee and was a member of the College Football Playoff Selection Committee. Additionally, he participated in the NCAA’s Management Council, the Committee on Infractions, the Executive Committee, the Football Rules Committee, and the President’s Commission Liaison Committee. As the first Black president of the National Association of Collegiate Directors of Athletics (NACDA) and a former president of the Division I-A Athletics Directors Association, Smith was the Director of Athletics at Arizona State from 2000 to 2005, at Iowa State from 1993 to 2000 and at Eastern Michigan from 1986 to 1993. He played football as an undergraduate at Notre Dame, where he was a defensive end on the 1973 national championship team and earned a bachelor’s degree in business administration. After graduation, he joined the coaching staff at Notre Dame and contributed to the Irish victory in the 1977 national championship.

About Robert J. Sweeney

Since 2019, Mr. Sweeney has served as the President of Sycamore Partners, a private equity firm focused on consumer, distribution, and retail-related investments. Before joining Sycamore Partners, he spent 22 years at Goldman Sachs, most recently as a partner and Global Head of the Consumer/Retail Investment Banking Group. During his tenure at Goldman Sachs, he provided advisory support to Under Armour on various matters, including the company’s initial public offering in 2005. Mr. Sweeney served as an officer in the U.S. Navy’s Submarine Force from 1989 to 1995, holding various roles aboard the USS Annapolis and at the Submarine Officer Advanced Course training command. He graduated from the Wharton School of the University of Pennsylvania with a bachelor’s degree and MBA, and he was recognized as a Palmer Scholar.

About Under Armour, Inc.

Under Armour, Inc., headquartered in Baltimore, Maryland, is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Designed to empower human performance, Under Armour’s innovative products and experiences are engineered to make athletes better. For further information, please visit http://about.underarmour.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/under-armour-appoints-dawn-n-fitzpatrick-eugene-d-smith-and-robert-j-sweeney-to-its-board-of-directors-302428276.html

SOURCE Under Armour, Inc.